

TITAN PHARMACEUTICALS INC  
Form 8-K  
February 27, 2013

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act 1934

Date of Report (Date of earliest event reported): February 27, 2013

## Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation)

0-27436  
(Commission  
File Number)

94-3171940  
(IRS Employer  
Identification No.)

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

400 Oyster Point Blvd., Suite 505, South San Francisco, CA

(Address of Principal Executive Offices)

94080

(Zip Code)

Registrant's telephone number, including area code: 650-244-4990

(Former Name or Former Address, is Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On February 27, 2013, Titan Pharmaceuticals, Inc. announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration is scheduled to review the Company's New Drug Application for Probuphine® for the maintenance treatment of adult patients with opioid dependence on March 21, 2013.

The press release dated February 27, 2013 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated February 27, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

Dated: February 27, 2013

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated February 27, 2013